IP Library Granted Patent US 9,441,228
Granted Patent B2
US 9,441,228 · App. 14/609,118 · Granted Sep 13, 2016

Post-synthetic chemical modification of RNA at the 2′-position of the ribose ring via “click” chemistry

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,441,228
App. No.
14/609,118
Granted
Sep 13, 2016
Kind
B2
Abstract

This invention relates to a 2′-modified RNA agent comprising at least one RNA strand containing a 2′-O substituent having an alkyne functional group attaching to the O atom at the 2′-position on one or more ribose rings, wherein the 2′-O substituent is located at one or more of positions 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, and 16, from 5′-end of the RNA strand. This invention also relates to a 2′-modified RNA agent comprising at least one RNA strand containing a 2′-O substituent having a triazole functional group attaching to the O atom at the 2′-position on one or more ribose rings, wherein the 2′-O substituent is located at one or more of positions 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, and 16, from 5′-end of the RNA strand.

Claims (18)

1. A 2′-modified siRNA, comprising at least one RNA strand containing a 2′-O substituent having an alkyne functional group at the 2′-position on one or more ribose rings, wherein the 2′-O substituent is located at one or more of positions 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, and 16, from 5′-end of the RNA strand.

2. The 2′-modified siRNA of claim 1 , wherein the 2′-O substituent is located at one or more of positions 4, 9, 13, and 14.

3. The 2′-modified siRNA of claim 1 , wherein the 2′-O substituent is located at one or more of positions 7, 8, 9, and 10.

4. The 2′-modified siRNA of claim 1 , wherein the RNA strand contains a 2′-O substituent having an alkyne functional group at the 2′-position on two or more ribose rings.

5. The 2′-modified siRNA of claim 1 , wherein the siRNA is a miRNA (micro RNA).

6. The 2′-modified siRNA of claim 1 , wherein the siRNA comprises a guide (antisense) strand, and the 2′-O substituent is contained in the guide strand.

7. The 2′-modified siRNA of claim 1 , wherein the siRNA comprises a passenger (sense) strand, and the 2′-O substituent is contained in the passenger strand.

8. The 2′-modified siRNA agent of claim 1 , wherein the RNA strand has a length of about 19 to 21 nucleotides.

9. The 2′-modified RNA agent of claim 1 , wherein the alkyne functional group is a propargyl moiety attaching to the oxygen atom of the 2′-O substituent.

10. A 2′-modified siRNA, comprising at least one RNA strand containing a 2′-O substituent having a triazole functional group at the 2′-position on one or more ribose rings, wherein the 2′-O substituent is located at one or more of positions 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, and 16, from 5′-end of the RNA strand.

11. The 2′-modified siRNA of claim 10 , wherein the 2′-O substituent is located at one or more of positions 4, 9, 13, and 14.

12. The 2′-modified siRNA of claim 10 , wherein the 2′-O substituent is located at one or more of positions 7, 8, 9, and 10.

13. The 2′-modified siRNA of claim 10 , wherein the RNA strand contains a 2′-O substituent having a triazole functional group at the 2′-position on two or more ribose rings.

14. The 2′-modified siRNA of claim 10 , wherein the RNA strand contains a 2′-O substituent having a triazole functional group at the 2′-position on three or more ribose rings.

15. The 2′-modified siRNA of claim 10 , wherein the siRNA comprises a guide (antisense) strand, and the 2′-O substituent is contained in the guide strand.

16. The 2′-modified siRNA of claim 10 , wherein the siRNA comprises a passenger (sense) strand, and the 2′-O substituent is contained in the passenger strand.

17. The 2′-modified siRNA of claim 10 , wherein the triazole functional group further comprises a lipid, sugar, protein, peptide, poly(ethylene)glycols, or antibody moiety.

18. The 2′-modified siRNA of claim 10 , wherein the triazole functional group further comprises benzyl or modified benzyl, ethyl-carboxymethyl, N-acetylgalactosamine, or PEG or amino-PEG.

Assignments (1)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →